Efficacy of NAC for the Prevention and Relief of PIPN in Women With Ovarian, Tubal, and Peritoneal Cancer - Trial NCT05539053
Access comprehensive clinical trial information for NCT05539053 through Pure Global AI's free database. This phase not specified trial is sponsored by Rajavithi Hospital and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rajavithi Hospital
Timeline & Enrollment
N/A
Nov 01, 2022
Dec 30, 2023
Primary Outcome
Paclitaxel-induce peripheral neuropathy
Summary
Ovarian cancer is third most common gynecologic cancer in Thai woman, treatment including
 surgery followed by chemotherapy.
 
 Patient usually received paclitaxel every 3 week for 6 cycles, paclitaxel induce peripheral
 neuropathy is common dose dependent side effect which can disturb quality of life, result in
 chemotherapy dose reduction or discontinuation leading to poor prognosis and decreased
 survival Mechanism of PIPN including inflammation, promotion of microtubule polymerization
 and inhibition of depolymerization, and oxidative stress N-acetylcysteine is acetylated form
 of l-cysteine, might reduce oxidative stress. NAC can restore glutathione level, which is
 potent natural antioxidant. NAC might reduce PIPN
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05539053
Non-Device Trial